Data from Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations

• DOI: 10.1158/1535-7163.c.7311494
• Publication Date: 2024-07-02T11:09:49Z
• Authors: Funda Meric-Bernstam; Michael W. Lloyd; Soner Koc; Yvonne A. Evrard; Lisa M. McShane; Michael T. Lewis; Kurt W. Evans; Dali Li; Lawrence Rubinstein; Alana Welm; Dennis A. Dean; Anuj Srivastava; Jeffrey W. Grover; Min J. Ha; Huiqin Chen; Xuelin Huang; Kaushik Varadarajan; Jing Wang; Jack A. Roth; Bryan Welm; Ramaswamy Govinden; Li Ding; Salma Kaochar; Nicholas Mitsiades; Luis Carvajal-Car...; Meenhard Herylyn; Michael A. Davies; Geoffrey I. Shapiro; Ryan Fields; Jose G. Trevino; Joshua C. Harrell; James H. Doroshow; Jeffrey H. Chuang; Jeffrey A. Moscow
• Keywords: Cancer Therapy; Identification

<div>Abstract<p>Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to <i>in vivo</i> tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison different studies determination whether PDX experiment has produced evidence needed consider new therapy promising. We present consensus recommendations activity, providing public access suite tools analyses. expect that harmonizing study design assessing analytical will enhance information exchange facilitate identification promising novel therapies biomarkers guiding therapy.</p></div>